DM
Therapeutic Areas
EpiPharm Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Artemisinin-based Topical Formulation (Artemether) | Seborrhoeic Keratosis | Phase 2/3 |
| Artemisinin-based Topical Formulation | Melanocytic Lesions | Clinical-Stage |
| Proprietary Multi-Active Artemisia Composition | Prevention & Treatment of Dysplastic Epidermal Cell Growth | Preclinical/Clinical-Stage |
Leadership Team at EpiPharm
DR
Dr. Rosemarie Sift Carter
Chief Executive Officer (CEO)
DR
Dr. Robert Carter
Head of Development and Regulatory
PR
Prof. R. Haynes
Advisor, Medicinal Chemistry
PA
Prof. A. Dayan
Advisor, Preclinical Safety
DA
Dr. A. Watkinson
Advisor, Formulation Development